Clinical Trial to Evaluate Papilocare® Gel Efficacy Into Repairment of Cervical Lesions Caused by HPV

HPV Infection Clinical Trial

— PAPILOCAN  

Official title:

Estudio clínico, Aleatorizado, Doble Ciego, Paralelo, Controlado Con Placebo Para Evaluar la Eficacia Del Gel Papilocare® en la reparación de Lesiones Cervicales Causadas Por VPH. Randomized, Double-blind, Parallel, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Papilocare® Gel in the Repairment of Cervical Lesions Caused by HPV.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04210336
• Other study ID #: PAPILOCAN
• Status: Completed
• Phase: N/A
• Start date: August 7, 2018
• Est. completion date: January 20, 2023

Study information

• Verified date: December 2022
• Source: Procare Health Iberia S.L.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Clinical Trial phase III, randomized, double-blind, placebo-controlled and parallel-group clinical trial to evaluate the efficacy of Papilocare gel in the repair of cervical lesions caused by HPV. The study is divided into two parts. All patients included in the study will be randomized (1: 1) to one of the 2 study groups, Papilocare or placebo, using a randomization list and in double-blind conditions.

Description:

Phase III, randomized, double-blind, placebo-controlled and parallel-group clinical trial to evaluate the efficacy of Papilocare gel in the repair of cervical lesions caused by HPV. The study is divided into two parts. All patients included in the study will be randomized (1: 1) to one of the 2 study groups, Papilocare or placebo, using a randomization list and in double-blind conditions. The study is divided into 2 parts, the first 100 randomized patients will receive treatment with an administration regimen in both arms: 1 cannula / day for 1 month + 1 cannula on alternate days for 5 months (except for menstruation days). The second part of the study, randomized patients from position 101 to 200, will receive treatment with an administration regimen in both arms: 1 cannula / day for 3 months + 1 cannula on alternate days for 3 months (except the days of menstruation). Duration of treatment: 6 months Total study duration: 13 months in 5 visits: selection visit, V0 or randomization visit (30 days), V1(Month 3), V2 (Month 6), V3 (Month 12).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: January 20, 2023
• Est. primary completion date: November 30, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 30 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Woman between the ages of 30 and 65 (both included).

2. Able to read and understand the Patient Information Sheet and informed consent

3. Accept participation in the study and sign the Informed Consent.

4. Cytological result of ASC-US or LSIL, with concordant colposcopic image, at most 3 months before the selection visit. It is considered concordant with ASCUS and LSIL, a colposcopic result of normality, of non-specific findings or of type 1 changes.

5. Positive HPV according to cobas 4800 technique (high-risk HPV) carried out in a selection visit (or positive available at most 3 months prior to the baseline visit).

6. Women vaccinated and not vaccinated against HPV.

7. Is able, at the discretion of the researcher, to comply with the requirements of the study and without impediments to follow the instructions and assessments throughout it.

Exclusion Criteria:

1. Clinically relevant alterations of the immune system or any other autoimmune disease or in treatment with immunosuppressants.

2. Other cytological results other than those provided for in the inclusion criteria.

3. Baseline LSIL biopsies with CIN-3.

4. Abnormal undiagnosed genital bleeding (during the 6 months prior to the selection visit)

5. Other symptomatic vulvovaginal infections.

6. Surgical cervical excision in the last year or total hysterectomy.

7. Previous history of gynecological cancer.

8. Participation in any other clinical trial at present or in the 4 weeks prior to inclusion of the study.

9. Any planned surgery that precludes correct compliance with the guideline.

10. Use of vaginal contraceptives or other vaginal hormonal treatments.

11. Contraindications to the use of Papilocare® gel or known allergies to any of its components.

12. Women of childbearing age who do not use effective contraceptive methods, pregnant women, with suspected pregnancy or breastfeeding.

Related Conditions & MeSH terms

• HPV Infection
• Lesion Cervix
• Papillomavirus Infections

Intervention

Device:
• PAPILOCARE
Papilocare®: Vaginal Gel based on Coriolus versicolor, medical device class IIa. Route of administration: topical (vaginal). Papilocare® consists of the following ingredients: hyaluronic acid niosomes, ß-glucans (magnolol, honokiol and carboxymethyl betaglucan) niosomes, BioEcolia® (Alpha-oligoglycan), Coriolus versicolor, Azadirachta indica (Neem) extract, Centella asiatica and Aloe vera.
• PLACEBO
The placebo consists of a carrier gel with the absence of the active ingredients of Papilocare®.

Locations

Country	Name	City	State
Spain	Hospital Universitario Nuestra Señora de la Candelaria	Santa Cruz de Tenerife	Tenerife

Sponsors (1)

Lead Sponsor	Collaborator
Procare Health Iberia S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change of biopsy results (optional)	Only in cases that a biopsy has been performed per routine, the change or maintenance of biopsy results will be evaluated.	3 and 6 months.
Primary	cervical mucosal repair	Percentage of patients with cervical lesions negativization confirmed be cytology and accordance colposcopy , at 6 months will be used to evaluate the main variables, degree of cervical mucosal repair in HPV-positive women with ASC-US or LSIL.	6 months
Secondary	Reepithelialization degree of the cervical mucosa	Percentage of patients with negativity of cervical lesions by cytology and accordance colposcopy, at 3 months	at 3 months
Secondary	Percentage of patients with Viral clearance	Percentage of patients with initial HPV clearance measured by PCR at 3 and 6 months.	3 and 6 months.
Secondary	Vaginal health status measured by vaginal health index (VHI)	Changes in the VHI (vaginal health index -Bachmann) at 3 and 6 months.; VHI was developed in order to objectively assess female urogenital health (Bachmann GMaturitas. 1995 Dec; 22 Suppl():S1-S5.). This test evaluates overall elasticity, fluid secretion type and consistency, vaginal pH, epithelial mucosa and moisture. Minimum score is 5 and maximum is 25. Lower scores corresponds to greater urogenital atrophy.	3 and 6 months.
Secondary	Stress perceived by patients measured by PSS-14 (Perceived Stress Scale 14 items)	Changes PSS-14 scale (Perceived Stress Scale 14 items) at 3 and 6 months.; The PSS-14 is comprised of 14 items, score ranges from 0-56, with higher scores indicating greater perceived stress	3 and 6 months.
Secondary	Safety and tolerability of Papilocare® gel: Record of the incidence, nature and severity of adverse events	Record of the incidence, nature and severity of adverse events: during the 6 months of treatment duration.	6 months
Secondary	Satisfaction degree with Papilocare gel use: Likert type scale	Patients satisfaction degree with papilocare gel use as treatment will be evaluated by a likert type scale.; A Likert scale is a psychometric scale commonly involved in research that employs questionnaires. It is the most widely used approach to scaling responses in survey research.Likert scaling assumes distances between each choice (answer option) are equal. Higher scores corresponds to better satisfaction with papilocare gel use.	3 and 6 months.